top of page
vinnytsia-ukraine-december-28-2017-offset-printing-process-ready-newspaper-print-mashine.j

DISCOVER OUR PIONEERING CONTRIBUTIONS TO ONCOLOGY THROUGH PRESTIGIOUS JOURNALS AND PLATFORMS LIKE ASCO, ESMO, AND SABCS. ELEVATE YOUR INSIGHTS WITH OUR CUTTING-EDGE CLINICAL TRIAL PUBLICATIONS.

EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT

PUBLICATIONS

Publications

THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.

STUDY

OFFICIAL TITLE

DISEASE

JOURNAL/
CONGRESS

YEAR

DOWNLOAD

Publications

ORPHEUS

Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study

PENILE

(Journal) European Urology Oncology

2024

ORPHEUS
Publications

TUXEDO-3

Patritumab deruxtecan (HER3-DXd) in active brain metastases from metastatic breast and non-small cell lung cancers, and leptomeningeal disease from advanced solid tumors: The TUXEDO-3 phase II trial.

BREAST; LUNG

ASCO

2024

TUXEDO-3
Publications

PHERGAIN

Comparing 18F-FDG positron emission tomography (PET) and breast magnetic resonance imaging (MRI) to predict pathological complete response (pCR) and 3-year invasive disease-free survival (3-y iDFS) in patients (pts) with HER2+ early breast cancer (EBC): An unplanned exploratory analysis of PHERGain trial.

BREAST

ASCO

2024

PHERGAIN
Publications

PATHFINDER

Ipatasertib (IPA) combined with non-taxane chemotherapy (CT) for patients (pts) with previously treated advanced triple-negative breast cancer (aTNBC): The PATHFINDER phase IIa trial.

BREAST

ASCO

2024

PATHFINDER
Publications

I3LUNG

The impact of decision tools during oncological consultation with lung cancer patients: a systematic-review within the i3LUNG project

LUNG

(Journal) Cancer Medicine

2024

I3LUNG
Publications

TUXEDO-3

Patritumab deruxtecan (HER3-DXd) in active brain metastases from metastatic breast and non-small cell lung cancers, and leptomeningeal disease from advanced solid tumors: The TUXEDO-3 phase II trial.

LUNG

ASCO

2024

TUXEDO-3
Publications

ORPHEUS

Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study

PENILE

(Journal) European Urology Oncology

2024

ORPHEUS
Publications

I3LUNG

The impact of decision tools during oncological consultation with lung cancer patients: A systematic review within the I3LUNG project

LUNG

(Journal) Nature Cancer

2024

I3LUNG
Publications

PHERGAIN

Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial

BREAST

(Journal) The Journal of Nuclear Medicine

2024

PHERGAIN
Publications

PHERGain

Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and
pathological complete response (pCR) in HER2-positive early breast cancer (EBC):
An exploratory analysis of the PHERGain trial

BREAST

(Journal) Breast Cancer Research and Treatment

2024

PHERGain
Publications

I3LUNG

The impact of decision tools during oncological consultation with lung cancer patients: a systematic-review within the i3LUNG project

LUNG

(Journal) Cancer Medicine

2024

I3LUNG
Publications

PHERGAIN

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

BREAST

(Journal) The Lancet

2024

PHERGAIN
Publications

Other MEDSIR related articles

home_fondo_cuadritos2.jpg
"
WE TURN THE BEST CLINICAL RESEARCH IDEAS INTO A BRIGHTER FUTURE FOR CANCER PATIENTS.
bottom of page